

American National Standard

ANSI/AAMI/ISO 11137-1:2006

Sterilization of health care products—Radiation— Part 1: Requirements for development, validation, and routine control of a sterilization process for medical devices

The Objectives and Uses of AAMI Standards and Recommended Practices

It is most important that the objectives and potential uses of an AAMI product standard or recommended practice are clearly understood. The objectives of AAMI's technical development program derive from AAMI's overall mission: the advancement of medical instrumentation. Essential to such advancement are (1) a continued increase in the safe and effective application of current technologies to patient care, and (2) the encouragement of new technologies. It is AAMI's view that standards and recommended practices can contribute significantly to the advancement of medical instrumentation, provided that they are drafted with attention to these objectives and provided that arbitrary and restrictive uses are avoided.

A voluntary *standard* for a *medical device* recommends to the manufacturer the information that should be provided with or on the product, basic safety and performance criteria that should be considered in qualifying the device for clinical use, and the measurement techniques that can be used to determine whether the device conforms with the safety and performance criteria and/or to compare the performance characteristics of different products. Some standards emphasize the information that should be provided with the device, including performance characteristics, instructions for use, warnings and precautions, and other data considered important in ensuring the safe and effective use of the device in the clinical environment. Recommending the disclosure of performance characteristics often necessitates the development of specialized test methods to facilitate uniformity in reporting; reaching consensus on these tests can represent a considerable part of committee work. When a drafting committee determines that clinical concerns warrant the establishment of *minimum* safety and performance criteria, referee tests must be provided and the reasons for establishing the criteria must be documented in the rationale.

A *recommended practice* provides guidelines for the use, care, and/or processing of a medical device or system. A recommended practice does not address device performance *per se*, but rather procedures and practices that will help ensure that a device is used safely and effectively and that its performance will be maintained.

Although a device standard is primarily directed to the manufacturer, it may also be of value to the potential purchaser or user of the device as a fume of reference for device evaluation. Similarly, even though a recommended practice is usually oriented towards health care professionals, it may be useful to the manufacturer in better understanding the environment in which a medical device will be used. Also, some recommended practices, while not addressing device performance criteria, provide guidelines to industrial personnel on such subjects as sterilization processing, methods of collecting data to establish safety and efficacy, human engineering, and other processing or evaluation techniques; such guidelines may be useful to health care professionals in understanding industrial practices.

In determining whether an AAMI standard or recommended practice is relevant to the specific needs of a potential user of the document, several important concepts must be recognized:

All AAMI standards and recommended practices are *voluntary* (unless, of course, they are adopted by government regulatory or procurement authorities). The application of a standard or recommended practice is solely within the discretion and professional judgment of the user of the document.

Each AAMI standard or recommended practice reflects the collective expertise of a committee of health care professionals and industrial representatives, whose work has been reviewed nationally (and sometimes internationally). As such, the consensus recommendations embodied in a standard or recommended practice are intended to respond to clinical needs and, ultimately, to help ensure patient safety. A standard or recommended practice is limited, however, in the sense that it responds generally to perceived risks and conditions that may not always be relevant to specific situations. A standard or recommended practice is an important *reference* in responsible decision-making, but it should never *replace* responsible decision-making.

Despite periodic review and revision (at least once every five years), a standard or recommended practice is necessarily a static document applied to a dynamic technology. Therefore, a standards user must carefully review the reasons why the document was initially developed and the specific rationale for each of its provisions. This review will reveal whether the document remains relevant to the specific needs of the user.

Particular care should be taken in applying a product standard to existing devices and equipment, and in applying a recommended practice to current procedures and practices. While observed or potential risks with existing equipment typically form the basis for the safety and performance criteria defined in a standard, professional judgment must be used in applying these criteria to existing equipment. No single source of information will serve to identify a particular product as "unsafe". A voluntary standard can be used as one resource, but the ultimate decision as to product safety and efficacy must take into account the specifics of its utilization and, of course, cost-benefit considerations. Similarly, a recommended practice should be analyzed in the context of the specific needs and resources of the individual institution or firm. Again, the rationale accompanying each AAMI standard and recommended practice is an excellent guide to the reasoning and data underlying its provision.

In summary, a standard or recommended practice is truly useful only when it is used in conjunction with other sources of information and policy guidance and in the context of professional experience and judgment.

INTERPRETATIONS OF AAMI STANDARDS AND RECOMMENDED PRACTICES

Requests for interpretations of AAMI standards and recommended practices must be made in writing, to the Manager for Technical Development. An official interpretation must be approved by letter ballot of the originating committee and subsequently reviewed and approved by the AAMI Standards Board. The interpretation will become official and representation of the Association only upon exhaustion of any appeals and upon publication of notice of interpretation in the "Standards Monitor" section of the *AAMI News*. The Association for the Advancement of Medical Instrumentation disclaims responsibility for any characterization or explanation of a standard or recommended practice which has not been developed and communicated in accordance with this procedure and which is not published, by appropriate notice, as an *official interpretation* in the *AAMI News*.

American National Standard

ANSI/AAMI/ISO 11137-1:2006
(Combined revision [in whole or in part]
of ANSI/AAMI/ISO 11137:1994 and A1:2002
and ANSI/AAMI/ISO TIR15843:2000)

Sterilization of health care products—Radiation— Part 1: Requirements for development, validation, and routine control of a sterilization process for medical devices

Approved 9 December 2005 by
Association for the Advancement of Medical Instrumentation

Approved 23 December 2005 by
American National Standards Institute

Abstract: Specifies requirements for validation, process control, and routine monitoring in the radiation sterilization for health care products. It applies to continuous and batch type gamma irradiators using the radionuclides ^{60}Co and ^{137}Cs , and to irradiators using a beam from an electron or X-ray generator.

Keywords: health care products, medical equipment, sterilization, radiation, gamma, electron beam, bremsstrahlung, X-ray

AAMI Standard

This Association for the Advancement of Medical Instrumentation (AAMI) standard implies a consensus of those substantially concerned with its scope and provisions. The existence of an AAMI standard does not in any respect preclude anyone, whether they have approved the standard or not, from manufacturing, marketing, purchasing, or using products, processes, or procedures not conforming to the standard. AAMI standards are subject to periodic review, and users are cautioned to obtain the latest editions.

CAUTION NOTICE: This AAMI standard may be revised or withdrawn at any time. AAMI procedures require that action be taken to reaffirm, revise, or withdraw this standard no later than five years from the date of publication. Interested parties may obtain current information on all AAMI standards by calling or writing AAMI.

All AAMI standards, recommended practices, technical information reports, and other types of technical documents developed by AAMI are *voluntary*, and their application is solely within the discretion and professional judgment of the user of the document. Occasionally, voluntary technical documents are adopted by government regulatory agencies or procurement authorities, in which case the adopting agency is responsible for enforcement of its rules and regulations.

Published by

Association for the Advancement of Medical Instrumentation
1110 N. Glebe Road, Suite 220
Arlington, VA 22201-4795

© 2006 by the Association for the Advancement of Medical Instrumentation

All Rights Reserved

This publication is subject to copyright claims of ISO, ANSI, and AAMI. No part of this publication may be reproduced or distributed in any form, including an electronic retrieval system, without the prior written permission of AAMI. All requests pertaining to this draft should be submitted to AAMI. It is illegal under federal law (17 U.S.C. § 101, *et seq.*) to make copies of all or any part of this document (whether internally or externally) without the prior written permission of the Association for the Advancement of Medical Instrumentation. Violators risk legal action, including civil and criminal penalties, and damages of \$100,000 per offense. For permission regarding the use of all or any part of this document, contact AAMI, 1110 N. Glebe Road, Suite 220, Arlington, VA 22201-4795. Phone: (703) 525-4890; Fax: (703) 525-1067.

Printed in the United States of America

ISBN 1-57020-253-2

Contents

Page

Glossary of equivalent standards	iv
Committee representation.....	vi
Background of AAMI adoption of ISO 11137-1:2006	ix
Foreword	x
Introduction	xi
1 Scope.....	1
2 Normative references	2
3 Terms and definitions.....	2
4 Quality management system elements.....	9
4.1 Documentation	9
4.2 Management responsibility.....	9
4.3 Product realization.....	9
4.4 Measurement, analysis and improvement — Control of nonconforming product.....	9
5 Sterilizing agent characterization.....	10
5.1 Sterilizing agent	10
5.2 Microbicidal effectiveness	10
5.3 Material effects	10
5.4 Environmental considerations	10
6 Process and equipment characterization.....	10
6.1 Process	10
6.2 Equipment.....	10
7 Product definition	12
8 Process definition.....	13
8.1 Establishing the maximum acceptable dose	13
8.2 Establishing the sterilization dose.....	13
8.3 Specifying the maximum acceptable dose and the sterilization dose.....	13
8.4 Transference of maximum acceptable, verification, or sterilization dose between radiation sources	14
9 Validation	14
9.1 Installation qualification.....	14
9.2 Operational qualification.....	15
9.3 Performance qualification.....	16
9.4 Review and approval of validation	16
10 Routine monitoring and control	18
11 Product release from sterilization	18
12 Maintaining process effectiveness	19
12.1 Demonstration of continued effectiveness	19
12.2 Recalibration	21
12.3 Maintenance of equipment.....	21
12.4 Requalification of equipment.....	22
12.5 Assessment of change	22
Annex A (informative) Guidance	23
Bibliography	39

Glossary of equivalent standards

International Standards adopted in the United States may include normative references to other International Standards. For each International Standard that has been adopted by AAMI (and ANSI), the table below gives the corresponding U.S. designation and level of equivalency to the International Standard. Note: Documents are sorted by international designation.

Other normatively referenced International Standards may be under consideration for U.S. adoption by AAMI; therefore, this list should not be considered exhaustive.

International designation	U.S. designation	Equivalency
IEC 60601-1:2005	ANSI/AAMI ES60601-1:2005	Major technical variations
IEC 60601-1-2:2001 and Amendment 1:2004	ANSI/AAMI/IEC 60601-1-2:2001 and Amendment 1:2004	Identical
IEC 60601-2-04:2002	ANSI/AAMI DF80:2003	Major technical variations
IEC 60601-2-19:1990 and Amendment 1:1996	ANSI/AAMI II36:2004	Major technical variations
IEC 60601-2-20:1990 and Amendment 1:1996	ANSI/AAMI II51:2004	Major technical variations
IEC 60601-2-21:1994 and Amendment 1:1996	ANSI/AAMI/IEC 60601-2-21 and Amendment 1:2000 (consolidated texts)	Identical
IEC 60601-2-24:1998	ANSI/AAMI ID26:2004	Major technical variations
IEC TR 60878:2003	ANSI/AAMI/IEC TIR60878:2003	Identical
IEC TR 62296:2003	ANSI/AAMI/IEC TIR62296:2003	Identical
IEC TR 62348:200x ¹	ANSI/AAMI/IEC TIR62348:2006	Identical
ISO 5840:2005	ANSI/AAMI/ISO 5840:2005	Identical
ISO 7198:1998	ANSI/AAMI/ISO 7198:1998/2001/(R)2004	Identical
ISO 7199:1996	ANSI/AAMI/ISO 7199:1996/(R)2002	Identical
ISO 10993-1:2003	ANSI/AAMI/ISO 10993-1:2003	Identical
ISO 10993-2:1992	ANSI/AAMI/ISO 10993-2:1993/(R)2001	Identical
ISO 10993-3:2003	ANSI/AAMI/ISO 10993-3:2003	Identical
ISO 10993-4:2002	ANSI/AAMI/ISO 10993-4:2002	Identical
ISO 10993-5:1999	ANSI/AAMI/ISO 10993-5:1999	Identical
ISO 10993-6:1994	ANSI/AAMI/ISO 10993-6:1995/(R)2001	Identical
ISO 10993-7:1995	ANSI/AAMI/ISO 10993-7:1995/(R)2001	Identical
ISO 10993-9:1999	ANSI/AAMI/ISO 10993-9:1999/(R)2005	Identical
ISO 10993-10:2002	ANSI/AAMI BE78:2002	Minor technical variations
ISO 10993-11:1993	ANSI/AAMI 10993-11:1993	Minor technical variations
ISO 10993-12:2002	ANSI/AAMI/ISO 10993-12:2002	Identical
ISO 10993-13:1998	ANSI/AAMI/ISO 10993-13:1999/(R)2004	Identical
ISO 10993-14:2001	ANSI/AAMI/ISO 10993-14:2001	Identical
ISO 10993-15:2000	ANSI/AAMI/ISO 10993-15:2000	Identical
ISO 10993-16:1997	ANSI/AAMI/ISO 10993-16:1997/(R)2003	Identical
ISO 10993-17:2002	ANSI/AAMI/ISO 10993-17:2002	Identical
ISO 10993-18:2005	ANSI/AAMI BE83:2006	Major technical variations

International designation	U.S. designation	Equivalency
ISO TS 10993-19:200x ¹	ANSI/AAMI/ISO TIR10993-19:2006	Identical
ISO TS 10993-20:200x ¹	ANSI/AAMI/ISO TIR10993-20:2006	Identical
ISO 11135:1994	ANSI/AAMI/ISO 11135:1994	Identical
ISO 11137-1:2006	ANSI/AAMI/ISO 11137-1:2006	Identical
ISO 11137-2:200x ¹	ANSI/AAMI/ISO 11137-2:2006	Identical
ISO 11137-3:2006	ANSI/AAMI/ISO 11137-3:2006	Identical
ISO 11138-1: 200x ¹	ANSI/AAMI/ISO 11138-1:2006	Identical
ISO 11138-2: 200x ¹	ANSI/AAMI/ISO 11138-2:2006	Identical
ISO 11138-3: 200x ¹	ANSI/AAMI/ISO 11138-3:2006	Identical
ISO 11138-4: 200x ¹	ANSI/AAMI/ISO 11138-4:2006	Identical
ISO 11138-5: 200x ¹	ANSI/AAMI/ISO 11138-5:2006	Identical
ISO TS 11139:2006	ANSI/AAMI/ISO 11139:2006	Identical
ISO 11140-1:2005	ANSI/AAMI/ISO 11140-1:2005	Identical
ISO 11140-5:2000	ANSI/AAMI ST66:1999	Major technical variations
ISO 11607-1:2006	ANSI/AAMI/ISO 11607-1:2006	Identical
ISO 11607-2:2006	ANSI/AAMI/ISO 11607-2:2006	Identical
ISO 11737-1: 2006	ANSI/AAMI/ISO 11737-1:2006	Identical
ISO 11737-2:1998	ANSI/AAMI/ISO 11737-2:1998	Identical
ISO 11737-3:2004	ANSI/AAMI/ISO 11737-3:2004	Identical
ISO 13485:2003	ANSI/AAMI/ISO 13485:2003	Identical
ISO 13488:1996	ANSI/AAMI/ISO 13488:1996	Identical
ISO 14155-1:2003	ANSI/AAMI/ISO 14155-1:2003	Identical
ISO 14155-2:2003	ANSI/AAMI/ISO 14155-2:2003	Identical
ISO 14160:1998	ANSI/AAMI/ISO 14160:1998	Identical
ISO 14161:2000	ANSI/AAMI/ISO 14161:2000	Identical
ISO 14937:2000	ANSI/AAMI/ISO 14937:2000	Identical
ISO TR 14969:2004	ANSI/AAMI/ISO TIR14969:2004	Identical
ISO 14971:2000 and A1:2003	ANSI/AAMI/ISO 14971:2000 and A1:2003	Identical
ISO 15223:2000, A1:2002, and A2:2004	ANSI/AAMI/ISO 15223:2000, A1:2001, and A2:2004	Identical
ISO 15225:2000 and A1:2004	ANSI/AAMI/ISO 15225:2000/(R)2006 and A1:2004/(R)2006	Identical
ISO 15674:2001	ANSI/AAMI/ISO 15674:2001	Identical
ISO 15675:2001	ANSI/AAMI/ISO 15675:2001	Identical
ISO TS 15843:2000	ANSI/AAMI/ISO TIR15843:2000	Identical
ISO 15882:2003	ANSI/AAMI/ISO 15882:2003	Identical
ISO TR 16142:2006	ANSI/AAMI/ISO TIR16142:2006	Identical
ISO 17664:2004	ANSI/AAMI ST81:2004	Major technical variations
ISO 17665-1:200x ¹	ANSI/AAMI/ISO 17665-1:2006	Identical
ISO 18472:200x ¹	ANSI/AAMI/ISO 18472:2006	Identical
ISO TS 19218:2005	ANSI/AAMI/ISO 19218:2005	Identical
ISO 25539-1:2003 and A1:2005	ANSI/AAMI/ISO 25539-1:2003 and A1:2005	Identical

¹In production

Committee representation

Association for the Advancement of Medical Instrumentation

Radiation Sterilization Working Group

The adoption of ISO 11137-1:2006 as an AAMI standard was initiated by the Radiation Sterilization Working Group of the AAMI Sterilization Standards Committee (AAMI/ST), which also functions as a U.S. Technical Advisory Group to the relevant work in the International Organization for Standardization (ISO). U.S. representatives from the AAMI Radiation Sterilization Working Group (U.S. Sub-TAG for ISO/TC 198/WG 2), chaired by Lisa Foster and Byron Lambert, played an active part in developing the ISO Standard.

Committee approval of this document does not necessarily imply that all committee members voted for its approval.

At the time this document was published, the **AAMI Radiation Sterilization Working Group** had the following members:

<i>Cochairs</i>	Lisa Foster Byron J. Lambert, PhD
<i>Members</i>	Chris B. Anderson, St Jude Medical Inc. Leonard S. Berman, PhD, Pall Medical Paul William Boentges, BS, Cardinal Health (MP&S) Anne F. Booth, MS, Conmed Corporation John Broad, NAMSA Trabue D. Bryans, AppTec Virginia C. Chamberlain, PhD, VC Chamberlain & Associates (Independent Expert) Rod Chu, MDS Nordion Gary N. Cranston, Consulting & Technical Svs/PCS Greg Crego, Ethox Corporation Kate Davenport, Northview Biosciences Douglas D. Davie, Sterilization Validation Services Brian R. Drumheller, CR Bard Barry P. Fairand, PhD (Independent Expert) Lisa Foster, Sterigenics International Ruth Garcia, Steris Corporation Joyce M. Hansen, JM Hansen & Associates (Independent Expert) Thomas L. Hansen, Terumo Medical Corporation Doug F. Harbrecht, Boston Scientific Corporation Deborah A. Havlik, Hospira Inc Arthur H. Heiss, PhD, Bruker BioSpin Corporation Craig M. Herring, Johnson & Johnson Carolyn L. Kinsley, Pharmaceutical Systems Inc. Byron J. Lambert, PhD, Guidant Corporation/Cardiac Rhythm Management Jeff Martin, Alcon Laboratories Inc. David Ford McGoldrick, BS, Abbott Laboratories James E. McGowan, Jr., BS, MBA, Sterility Assurance Laboratories Inc. Joseph M. Mello, Ethide Laboratories Inc. Russell D. Mills, Zimmer Inc. Gerry A. O'Dell, MS, Gerry O'Dell Consulting (Independent Expert) Frank Peacock, Jr., Bausch & Lomb Inc. Bryant Pearce, Clearant Inc. Manuel Saavedra, Jr., Kimberly-Clark Corporation Zenius V. Seliokas, Stericon Inc. Jon Seulean, Cobe Sterilization Services Inc. Harry L. Shaffer, Sterilization Consulting Services William N. Thompson, TYCO Healthcare/Kendall

Alternates

Richard L. Weisman, Fresenius Medical Care NA Dialysis Products Division
Patrick B. Weixel, FDA/CDRH
James L. Whitby, MA, MB, FRCP, University of Western Ontario (Independent Expert)
Thelma Wilcott, Becton Dickinson & Company
John Andrew Williams, BS, Baxter Healthcare Corporation
Martell Kress Winters, BS, SM, Nelson Laboratories Inc.
Lisa Baryschpolec, Johnson & Johnson
Harry F. Bushar, PhD, FDA/CDRH
Charles Cogdill, Boston Scientific Corporation
John DiCaro, TYCO Healthcare/Kendall
Joyce Kay Elkins, Zimmer Inc.
Niki Fidopiastis, Sterigenics International
Donna Horner, Guidant Corporation/Cardiac Rhythm Management
Joseph A. Hutson, Cardinal Health (MP&S)
Orlando C. Johnson, Hospira Inc.
Bert Kingsbury, Terumo Medical Corporation
Ezra Koski, A, Cobe Sterilization Services Inc.
Mary Malarkey, FDA/CDRH
Mary S. Mayo, CR Bard
Consuelo Lorraine McChesney, BS, Alcon Laboratories Inc.
Patrick J. McCormick, PhD, Bausch & Lomb Inc.
Dave Parente, NAMS
Timothy Ramsey, BS, Northview Biosciences
Mark Seybold, Baxter Healthcare Corporation
Ralph Stick, AppTec
John W. Walker, Steris Corporation
Wendy Wangsgard, PhD, Nelson Laboratories Inc.
David Weppner, Ethox Corporation

AAMI Sterilization Standards Committee

Cochairs

Victoria M. Hitchins, PhD
William E. Young

Members

Trabue D. Bryans, AppTec
Virginia C. Chamberlain, PhD, VC Chamberlain & Associates (Independent Expert)
Nancy Chobin, RN, CSPDM, St. Barnabas Healthcare System (Independent Expert)
Anne M. Cofie, CRCST, FCS, International Association of Healthcare Central Service Materiel Management
Charles Cogdill, Boston Scientific Corporation
Ramona Conner, RN, MSN, CNOR, Association of Perioperative Registered Nurses
Jacqueline Daley, Association for Professionals in Infection Control and Epidemiology
Kimbrell Darnell, CR Bard
Lisa Foster, Sterigenics International
James M. Gibson, Jr., JM Gibson Associates
Barbara J. Goodman, RN, BS, CNOR (Independent Expert)
Joel R. Gorski, PhD, NAMS
Deborah A. Havlik, Hospira Inc.
Victoria M. Hitchins, PhD, FDA/CDRH
Richard M. Johnson, MSc, BSc, Abbott Laboratories
Lois Atkinson Jones, MS (Independent Expert)
Byron J. Lambert, PhD, Guidant Corporation/Cardiac Rhythm Management
Colleen Patricia Landers, RN, Canadian Standards Association
David Liu, Johnson & Johnson
Jeff Martin, Alcon Laboratories Inc.
Patrick J. McCormick, PhD, Bausch & Lomb Inc.
Thomas K. Moore, Getinge USA
Barry F.J. Page, Barry Page Consulting (Independent Expert)
Nancy J. Rakiewicz, Ethox Corporation
Phil M. Schneider, 3M Healthcare
Michael H. Scholla, Dupont Nonwovens
Mark Seybold, Baxter Healthcare Corporation
Andrew Sharavara, Propper Manufacturing Co Inc.
Frank Sizemore, American Society for Healthcare Central Service Professionals

Gregory O. Stecklein, MS, MSM, Cardinal Health (MP&S)
William N. Thompson, TYCO Healthcare/Kendall
John W. Walker, Steris Corporation
James L. Whitby, MA, MB, FRCP, University of Western Ontario (Independent Expert)
Thelma Wilcott, Becton Dickinson & Company
Martell Kress Winters, BS, SM, Nelson Laboratories Inc.
William E. Young (Independent Expert)

Alternates

Lloyd Brown, TYCO Healthcare/Kendall
Lina C. Bueno, Dupont Nonwovens
Craig M. Herring, Johnson & Johnson
Clark W. Houghtling, Steris Corporation
Danny Hutson, Cardinal Health (MP&S)
Jim Kaiser, Bausch & Lomb Inc.
Susan G. Klacik, AS, BS, International Association of Healthcare Central Service Materiel
Management
Joseph J. Lasich, BS, Alcon Laboratories Inc.
Chiu Lin, PhD, FDA/CDRH
Lisa N. Macdonald, Becton Dickinson & Company
Ralph Makinen, Guidant Corporation/Cardiac Rhythm Management
Mary S. Mayo, CR Bard
David Ford McGoldrick, BS, Abbott Laboratories
Jerry R. Nelson, MS, PhD, Nelson Laboratories Inc.
Jeff Peltier, Boston Scientific Corporation
Janet Prust, 3M Healthcare
Mike Sadowski, Baxter Healthcare Corporation
Ralph Stick, AppTec
Jason Voisinet, Ethox Corporation
Valerie Welter, Hospira Inc.
William T. Young, Sterigenics International

NOTE—Participation by federal agency representatives in the development of this document does not constitute endorsement by the federal government or any of its agencies.

Background of AAMI adoption of ISO 11137-1:2006

The International Organization for Standardization (ISO) is a worldwide federation of national standards bodies. The United States is one of the ISO members that took an active role in the development of this standard.

The first edition of ISO 11137 was developed by ISO Technical Committee 198 to fill a need for an international standard for radiation sterilization of health care products. The standard was published in 1995 and was followed by several technical reports developed in ISO or in AAMI primarily to cover additional dose setting methods. During its systematic review of ISO 11137:1995 (adopted in the U.S. as ANSI/AAMI/ISO 11137:1994), ISO/TC 198 decided to revise the document by splitting it into three parts under the general title *Sterilization of health care products—Radiation*. The three parts are

- *Part 1: Requirements for development, validation, and routine control of a sterilization process for medical devices;*
- *Part 2: Establishing the sterilization dose; and*
- *Part 3: Guidance on dosimetric aspects.*

In addition, content from some of the technical reports developed since the first edition was published has been incorporated into the latest standards.

Part 1 of ISO 11137 has many of the same requirements as ISO 11137:1995, but is organized differently and has new terminology, e.g., product families, processing categories, process definition, and performance qualification (per ISO 13485).

New technical content includes

- the addition of a new dose option, 15 kGy, in addition to 25 kGy, for the establishment of a sterilization dose using the dose substantiation method
- operational qualification technical requirements
- options and requirements in defining the frequency of bioburden determination and dose audits.

Additionally, ISO 11137-1 provides a more comprehensive definition of irradiation and process specifications, and clarifies the requirements for equipment requalification as well as the criteria for transferring dose between facilities.

U.S. participation in ISO/TC 198 is organized through the U.S. Technical Advisory Group for ISO/TC 198, administered by the Association for the Advancement of Medical Instrumentation (AAMI). The United States made a considerable contribution to this standard.

Concurrent with the development of the U.S. position on the ISO 11137 series, the AAMI Radiation Sterilization Working Group (AAMI ST/WG 02) decided to adopt the three parts verbatim. Together, these documents supersede ANSI/AAMI/ISO 11137:1994 (and 2002 amendment), AAMI TIR27:2001, AAMI/ISO TIR13409:1996 (and 2000 amendment), and AAMI/ISO TIR15844:1998.

The concepts incorporated in this standard should not be considered inflexible or static. This standard, like any other, must be reviewed and updated periodically to assimilate progressive technological developments. To remain relevant, it must be modified as technological advances are made and as new data comes to light. Suggestions for improving this standard are invited. Comments on this standard are invited and should be sent to AAMI, Attn: Standards Department, 1110 N. Glebe Road, Suite 220, Arlington, VA 22201-4795.

NOTE—Beginning with the ISO foreword on page x, this American National Standard is identical to ISO 11137-1:2006.

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

International Standards are drafted in accordance with the rules given in the ISO/IEC Directives, Part 2.

The main task of technical committees is to prepare International Standards. Draft International Standards adopted by the technical committees are circulated to the member bodies for voting. Publication as an International Standard requires approval by at least 75 % of the member bodies casting a vote.

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights.

ISO 11137-1 was prepared by Technical Committee ISO/TC 198, *Sterilization of health care product*.

This first edition, together with ISO 11137-2 and ISO 11137-3, cancels and replaces ISO 11137:1995.

ISO 11137 consists of the following parts, under the general title *Sterilization of health care products — Radiation*:

- *Part 1: Requirements for development, validation, and routine control of a sterilization process for medical devices*
- *Part 2: Establishing the sterilization dose*
- *Part 3: Guidance on dosimetric aspects*

Introduction

A sterile medical device is one that is free of viable microorganisms. International Standards, which specify requirements for validation and routine control of sterilization processes, require, when it is necessary to supply a sterile medical device, that adventitious microbiological contamination of a medical device prior to sterilization be minimized. Even so, medical devices produced under standard manufacturing conditions in accordance with the requirements for quality management systems (see, for example, ISO 13485) may, prior to sterilization, have microorganisms on them, albeit in low numbers. Such medical devices are non-sterile. The purpose of sterilization is to inactivate the microbiological contaminants and thereby transform the non-sterile medical devices into sterile ones.

The kinetics of inactivation of a pure culture of microorganisms by physical and/or chemical agents used to sterilize medical devices can generally best be described by an exponential relationship between the numbers of microorganisms surviving and the extent of treatment with the sterilizing agent; inevitably this means that there is always a finite probability that a microorganism may survive regardless of the extent of treatment applied. For a given treatment, the probability of survival is determined by the number and resistance of microorganisms and by the environment in which the organisms exist during treatment. It follows that the sterility of any one medical device in a population subjected to sterilization processing cannot be guaranteed and the sterility of a processed population is defined in terms of the probability of there being a viable microorganism present on a medical device.

This part of ISO 11137 describes requirements that, if met, will provide a radiation sterilization process intended to sterilize medical devices, that has appropriate microbicidal activity. Furthermore, compliance with the requirements ensures that this activity is both reliable and reproducible so that predictions can be made, with reasonable confidence, that there is a low level of probability of there being a viable microorganism present on product after sterilization. Specification of this probability is a matter for regulatory authorities and may vary from country to country (see, for example, EN 556-1 and ANSI/AAMI ST67).

Generic requirements of the quality management system for design and development, production, installation and servicing are given in ISO 9001 and particular requirements for quality management systems for medical device production are given in ISO 13485. The standards for quality management systems recognize that, for certain processes used in manufacturing, the effectiveness of the process cannot be fully verified by subsequent inspection and testing of the product. Sterilization is an example of such a process. For this reason, sterilization processes are validated for use, the performance of the sterilization process is monitored routinely and the equipment is maintained.

Exposure to a properly validated, accurately controlled sterilization process is not the only factor associated with the provision of reliable assurance that the products are sterile and, in this regard, suitable for its intended use. Attention is therefore given to a number of considerations including:

- a) the microbiological status of incoming raw materials and/or components;
- b) the validation and routine control of any cleaning and disinfection procedures used on the product;
- c) the control of the environment in which the product is manufactured, assembled and packaged;
- d) the control of equipment and processes;
- e) the control of personnel and their hygiene;

- f) the manner and materials in which the product is packaged;
- g) the conditions under which product is stored.

This part of ISO 11137 describes the requirements for ensuring that the activities associated with the process of radiation sterilization are performed properly. These activities are described in documented work programs designed to demonstrate that the radiation process will consistently yield sterile products on treatment with doses falling within the predetermined limits.

The requirements are the normative parts of this part of ISO 11137 with which compliance is claimed. The guidance given in the informative annexes is not normative and is not provided as a checklist for auditors. The guidance provides explanations and methods that are regarded as being a suitable means for complying with the requirements. Methods other than those given in the guidance may be used, if they are effective in achieving compliance with the requirements of this part of ISO 11137.

The development, validation and routine control of a sterilization process comprise a number of discrete but interrelated activities; e.g. calibration, maintenance, product definition, process definition, installation qualification, operational qualification and performance qualification. While the activities required by this part of ISO 11137 have been grouped together and are presented in a particular order, this part of ISO 11137 does not require that the activities be performed in the order that they are presented. The activities required are not necessarily sequential, as the program of development and validation may be iterative. It is possible that performing these different activities will involve a number of separate individuals and/or organizations, each of whom undertake one or more of these activities. This part of ISO 11137 does not specify the particular individuals or organizations to carry out the activities.

Sterilization of health care products—Radiation— Part 1: Requirements for development, validation, and routine control of a sterilization process for medical devices

1 Scope

1.1 This part of ISO 11137 specifies requirements for the development, validation and routine control of a radiation sterilization process for medical devices.

NOTE Although the scope of this part of ISO 11137 is limited to medical devices, it specifies requirements and provides guidance that may be applicable to other products and equipment.

This part of ISO 11137 covers radiation processes employing irradiators using,

- a) the radionuclide ^{60}Co or ^{137}Cs ,
 - b) a beam from an electron generator
- or
- c) a beam from an X-ray generator.

1.2 This part of ISO 11137 does not specify requirements for development, validation and routine control of a process for inactivating the causative agents of spongiform encephalopathies such as scrapie, bovine spongiform encephalopathy and Creutzfeld-Jakob disease. Specific recommendations have been produced in particular countries for the processing of materials potentially contaminated with these agents.

NOTE See, for example, ISO 22442-1, ISO 22442-2, and ISO 22442-3.

1.2.1 This part of ISO 11137 does not detail specified requirements for designating a medical device as sterile.

NOTE Attention is drawn to regional and national requirements for designating medical devices as “sterile.” See, for example, EN 556-1 or ANSI/AAMI ST67.

1.2.2 This part of ISO 11137 does not specify a quality management system for the control of all stages of production of medical devices.

NOTE It is not a requirement of this part of ISO 11137 to have a complete quality management system during manufacture, but the elements of a quality management system that are the minimum necessary to control the sterilization process are normatively referenced at appropriate places in the text (see, in particular, Clause 4). Attention is drawn to the standards for quality management systems (see ISO 13485) that control all stages of production of medical devices, including the sterilization process. Regional and national regulations for the provision of medical devices might require implementation of a complete quality management system and the assessment of that system by a third party.

1.2.3 This part of ISO 11137 does not require that biological indicators be used for validation or monitoring of radiation sterilization, nor does it require that a pharmacopoeial test for sterility be carried out for product release.

1.2.4 This part of ISO 11137 does not specify requirements for occupational safety associated with the design and operation of irradiation facilities.

NOTE Attention is also drawn to the existence, in some countries, of regulations laying down safety requirements for occupational safety related to radiation.

1.2.5 This part of ISO 11137 does not specify requirements for the sterilization of used or reprocessed devices.

2 Normative references

The following referenced documents are indispensable for the application of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

ISO 10012-1, *Quality assurance requirements for measuring equipment — Part 1: Metrological confirmation system for measuring equipment*

ISO 11137-2:2006, *Sterilization of health care products — Radiation — Part 2: Establishing the sterilization dose*

ISO 11737-1, *Sterilization of medical devices — Microbiological methods — Part 1: Determination of a population of microorganisms on products*

ISO 11737-2, *Sterilization of medical devices — Microbiological methods — Part 2: Tests of sterility performed in the validation of a sterilization process*

ISO 13485:2003, *Medical devices — Quality management systems — Requirements for regulatory purposes*

3 Terms and definitions

For the purposes of this document, the following terms and definitions apply.

3.1

absorbed dose dose

quantity of ionizing radiation energy imparted per unit mass of a specified material

NOTE 1 The unit of absorbed dose is the gray (Gy) where 1 Gy is equivalent to the absorption of 1 J/kg.

NOTE 2 For the purposes of this part of ISO 11137, the term dose is used to mean “absorbed dose.”

3.2

bioburden

population of viable microorganisms on or in the product and/or sterile barrier system

[ISO/TS 11139:2006]

3.3

biological indicator

test system containing viable microorganisms providing a defined resistance to a specified sterilization process

[ISO/TS 11139:2006]

3.4

calibration

set of operations that establish, under specified conditions, the relationship between values of a quantity indicated by a measuring instrument or measuring system, or values represented by a material measure or a reference material, and the corresponding values realized by standards

[VIM:1993, definition 6.11]

3.5

change control

assessment and determination of the appropriateness of a proposed alteration to product or procedure

[ISO/TS 11139:2006]

3.6

correction

action to eliminate a detected nonconformity

NOTE A correction can be made in conjunction with corrective action (3.7).

[ISO 9000:2005]

3.7

corrective action

action to eliminate the cause of a detected nonconformity or other undesirable situation

NOTE 1 There can be more than one cause for a nonconformity.

NOTE 2 Corrective action is taken to prevent recurrence whereas “preventive action” (3.24) is taken to prevent occurrence.

NOTE 3 There is a distinction between correction and corrective action.

[ISO 9000:2005]

3.8

***D* value**

***D*₁₀ value**

time or radiation dose required to achieve inactivation of 90 % of a population of the test microorganism under stated conditions

NOTE For the purpose of the ISO 11137 series, the *D* value refers to the radiation dose necessary to achieve the 90 % reduction.

[ISO/TS 11139:2006]

3.9

development

act of elaborating a specification

[ISO/TS 11139:2006]

3.10

dose mapping

measurement of dose distribution and variability in material irradiated under defined conditions

3.11

dosimeter

device having a reproducible, measurable response to radiation, which can be used to measure the absorbed dose in a given system

[ISO/TS 11139:2006]

3.12

dosimetry

measurement of absorbed dose by the use of dosimeters

3.13

establish

determine by theoretical evaluation and confirm by experimentation

[ISO/TS 11139:2006]

3.14

fault

one or more of the process parameters lying outside of its/their specified tolerance(s)

[ISO/TS 11139:2006]

3.15

health care product(s)

medical device(s), including *in vitro* diagnostic medical device(s), or medicinal product(s), including biopharmaceutical(s)

[ISO/TS 11139:2006]

3.16

installation qualification

IQ

process of obtaining and documenting evidence that equipment has been provided and installed in accordance with its specification

[ISO/TS 11139:2006]

3.17

irradiation container

holder in which product is transported through the irradiator

NOTE The holder can be a carrier, cart, tray, product carton, pallet or other container.

3.18

irradiator operator

company or body responsible for irradiation of product

3.19

maximum acceptable dose

dose given in the process specification as the highest dose that can be applied to a defined product without compromising safety, quality or performance

3.20

medical device

instrument, apparatus, implement, machine, appliance, implant, *in vitro* reagent or calibrator, software, material or other similar or related article, intended by the manufacturer to be used, alone or in combination, for human beings for one or more of the specific purpose(s) of:

- diagnosis, prevention, monitoring, treatment or alleviation of disease;
- diagnosis, monitoring, treatment, alleviation of or compensation for an injury;
- investigation, replacement, modification, or support of the anatomy or of a physiological process;
- supporting or sustaining life;
- control of conception;
- disinfection of medical devices;
- providing information for medical purposes by means of *in vitro* examination of specimens derived from the human body;

and which does not achieve its primary intended action in or on the human body by pharmacological, immunological or metabolic means, but which may be assisted in its function by such means

[ISO 13485:2003]

NOTE This definition from ISO 13485:2003 has been developed by the Global Harmonization Task Force (GHTF 2002).

3.21

microorganism

entity of microscopic size, encompassing bacteria, fungi, protozoa and viruses

NOTE A specific standard might not require demonstration of the effectiveness of the sterilization process in inactivating all types of microorganisms, identified in the definition above, for validation and/or routine control of the sterilization process.

[ISO/TS 11139:2006]

3.22

operational qualification

OQ

process of obtaining and documenting evidence that installed equipment operates within predetermined limits when used in accordance with its operational procedures

[ISO/TS 11139:2006]

3.23

performance qualification

PQ

process of obtaining and documenting evidence that the equipment, as installed and operated in accordance with operational procedures, consistently performs in accordance with predetermined criteria and thereby yields product meeting its specification

[ISO/TS 11139:2006]

3.24

preventive action

action to eliminate the cause of a potential nonconformity or other undesirable potential situation

NOTE 1 There can be more than one cause for a potential nonconformity.

NOTE 2 Preventive action is taken to prevent occurrence whereas “corrective action” (3.7) is taken to prevent recurrence.

[ISO 9000:2005]

3.25

primary manufacturer

body responsible for the design and manufacture of a medical device, together with the safety and performance of that medical device when placed on the market

3.26

process interruption

intentional or unintentional stoppage of the irradiation process

3.27

process parameter

specified value for a process variable

NOTE The specification for a sterilization process includes the process parameters and their tolerances.

[ISO/TS 11139:2006]

3.28

process variable

condition within a sterilization process, changes in which alter microbicidal effectiveness

EXAMPLES Time, temperature, pressure, concentration, humidity, wavelength.

3.29

processing category

group of different product that can be sterilized together

NOTE Processing categories can be based on, for instance, composition, density or dose requirements.

3.30

product

result of a process

[ISO 9000:2005]

NOTE For the purposes of sterilization standards, product is tangible and can be raw material(s), intermediate(s), sub-assembly(ies) or health care product(s).

3.31

product family

group of different product that can be given the same sterilization dose

3.32

requalification

repetition of part of validation for the purpose of confirming the continued acceptability of a specified process

[ISO/TS 11139:2006]

3.33

services

supplies from an external source, needed for the function of equipment

EXAMPLES Electricity, water, compressed air, drainage.

3.34

specification

approved document stipulating requirements

3.35

specify

stipulate in detail within an approved document

[ISO/TS 11139:2006]

3.36

sterile

free from viable microorganisms

[ISO/TS 11139:2006]

3.37

sterility

state of being free from viable microorganisms

NOTE In practice, no such absolute statement regarding the absence of microorganisms can be proven (see **sterilization**) 3.39.

[ISO/TS 11139:2006]

3.38

sterility assurance level

SAL

probability of a single viable microorganism occurring on an item after sterilization

NOTE The term SAL takes a quantitative value, generally 10^{-6} or 10^{-3} . When applying this quantitative value to assurance of sterility, an SAL of 10^{-6} has a lower value but provides greater assurance of sterility than an SAL of 10^{-3} .

[ISO/TS 11139:2006]

3.39

sterilization

validated process used to render product free from viable microorganisms

NOTE In a sterilization process, the nature of microbial inactivation is exponential and thus the survival of a microorganism on an individual item can be expressed in terms of probability. While this probability can be reduced to a very low number it can never be reduced to zero [see “**sterility assurance level**” (3.38)].

[ISO/TS 11139:2006]

3.40

sterilization dose

minimum dose to achieve the specified requirements for sterility

3.41

sterilization process

series of actions or operations needed to achieve the specified requirements for sterility

NOTE This series of actions includes pretreatment of product (if necessary), exposure under defined conditions to the sterilizing agent and any necessary post treatment. The sterilization process does not include any cleaning, disinfection or packaging operations that precede sterilization.

[ISO/TS 11139:2006]

3.42

sterilizing agent

physical or chemical entity, or combination of entities having sufficient microbicidal activity to achieve sterility under defined conditions

[ISO/TS 11139:2006]

3.43

test for sterility

technical operation defined in an official pharmacopoeia performed on product following exposure to a sterilization process

[ISO/TS 11139:2006]

3.44

test of sterility

technical operation performed as part of development, validation or requalification to determine the presence or absence of viable microorganisms on product or portions thereof

[ISO/TS 11139:2006]

3.45

transit dose

dose absorbed during travel of product or source to or from the non-irradiation to the irradiation position

3.46

uncertainty of measurement

parameter, associated with the result of a measurement, that characterizes the dispersion of values that could reasonably be attributed to the measurand

[VIM 1993]

3.47

validation

documented procedure for obtaining, recording and interpreting the results required to establish that a process will consistently yield product complying with predetermined specifications

[ISO/TS 11139:2006]

4 Quality management system elements

4.1 Documentation

4.1.1 Procedures for development, validation, routine control and product release from sterilization shall be specified.

4.1.2 Documents and records required by this part of ISO 11137 shall be reviewed and approved by designated personnel (see 4.2.1). Documents and records shall be controlled in accordance with the applicable clauses of ISO 13485.

4.2 Management responsibility

4.2.1 The responsibility and authority for implementing and meeting the requirements described in this part of ISO 11137 shall be specified. Responsibility shall be assigned to competent personnel in accordance with the applicable clauses of ISO 13485.

4.2.2 If the requirements of this part of ISO 11137 are undertaken by organizations with separate quality management systems, the responsibilities and authority of each party shall be specified.

4.3 Product realization

4.3.1 Procedures for purchasing shall be specified. These procedures shall comply with the applicable clauses of ISO 13485.

4.3.2 Procedures for identification and traceability of product shall be specified. These procedures shall comply with the applicable clauses of ISO 13485.

4.3.3 A system complying with the applicable clauses of ISO 13485 or ISO 10012-1 shall be specified for the calibration of all equipment, including instrumentation for test purposes, used in meeting the requirements of this part of ISO 11137.

4.3.4 Dosimetry used in the development, validation and routine control of the sterilization process shall have measurement traceability to national or International Standards and shall have a known level of uncertainty.

4.4 Measurement, analysis, and improvement — Control of nonconforming product

Procedures for control of product designated as nonconforming and for correction, corrective action, and preventive action shall be specified. These procedures shall comply with the applicable clauses of ISO 13485.

5 Sterilizing agent characterization

5.1 Sterilizing agent

5.1.1 The type of radiation to be used in sterilization processing shall be specified.

5.1.2 For electrons or X-rays, the energy level of the electron beam shall be specified. If the energy level for electrons exceeds 10 MeV or the energy level for electrons used to generate X-rays exceeds 5 MeV, the potential for induced radioactivity in product shall be assessed. The outcome of the assessment and the rationale for decisions reached shall be documented.

5.2 Microbicidal effectiveness

The inactivation of microorganisms by radiation and the use of radiation in sterilization processes have been comprehensively documented in the literature. This literature provides knowledge of the manner in which the process variables affect microbial inactivation. Reference to these general studies on microbial inactivation is not required by this part of ISO 11137.

5.3 Material effects

The effects of radiation on a wide variety of materials used to manufacture medical devices have been comprehensively documented and the resultant documentation is of value to those designing and developing medical devices that are to be sterilized by radiation. This part of ISO 11137 does not require the performance of studies on material effects, but does require performance of studies of the effects of radiation on product (see 8.1).

5.4 Environmental considerations

The potential effect on the environment of the operation of the radiation sterilization process shall be assessed and measures to protect the environment shall be identified. This assessment, including potential impact (if any) shall be documented and measures for control (if identified), shall be specified and implemented.

6 Process and equipment characterization

6.1 Process

Process variables shall be identified and means of monitoring and controlling them shall be specified.

6.2 Equipment

6.2.1 The irradiator and its method of operation shall be specified. The specification of the irradiator shall be revised as necessary (see 12.5.1) and retained for the life of the irradiator (see 4.1.2).

6.2.2 Software used to control and/or monitor the process shall be prepared in accordance with a quality management system that provides documented evidence that the software meets its design intention.

6.2.3 For gamma irradiators, the specification shall at least describe:

- a) the irradiator and its characteristics;
- b) the type of radionuclide and its activity and the geometry of the gamma source;
- c) the premises, including the location of the irradiator;
- d) the means provided for the segregation of non-irradiated product from irradiated product (see 10.3 and 10.4);
- e) the construction and operation of any associated conveyor system;
- f) the conveyor path(s) and the range of conveyor speed;
- g) the dimensions, materials and nature of construction of the irradiation container(s);
- h) the manner of operating and maintaining the irradiator and any associated conveyor system;
- i) the means of indicating the position of the gamma source;
- j) the means of automatically returning the gamma source to the storage position and automatically ceasing conveyor movement if the process control timer or the conveyor system fails;
- k) the means of returning the gamma source to the storage position and automatically ceasing conveyor movement or identifying affected product if the gamma source is not at its intended position.

6.2.4 For electron beam irradiators the specification shall at least describe:

- a) the irradiator and its characteristics;
- b) the characteristics of the beam (electron energy and, if applicable, average beam current, scan width and scan uniformity);
- c) the premises including the location of the irradiator;
- d) the means provided for the segregation of non-irradiated product from irradiated product (see 10.3 and 10.4);
- e) the construction and operation of any associated conveyor system;
- f) the conveyor path(s) and the range of the conveyor speed;
- g) the dimensions, materials and nature of construction of the irradiation container(s);
- h) the manner of operating and maintaining the irradiator and any associated conveyor system;
- i) the means of indicating that the beam and the conveyor are operating;
- j) the means of ceasing irradiation if any failure of the conveyor occurs which affects the dose;
- k) the means of ceasing conveyor movement or identifying affected product if any fault in the beam occurs.

6.2.5 For X-ray irradiators, the specification shall at least describe:

- a) the irradiator and its characteristics;

- b) the characteristics of the beam (electron or X-ray energy and, if applicable, average beam current, scan width and scan uniformity);
- c) the dimension, materials and nature of construction of the X-ray converter;
- d) the premises including the location of the irradiator;
- e) the means provided for the segregation of non-irradiated product from irradiated product (see 10.3 and 10.4);
- f) the construction and operation of any associated conveyor system;
- g) the conveyor path(s) and the range of the conveyor speed;
- h) the dimensions, materials and construction of the irradiation container(s);
- i) the manner of operating and maintaining the irradiator and any associated conveyor system;
- j) the means of indicating that the beam and the conveyor are operating;
- k) the means of ceasing irradiation if any failure of the conveyor occurs which affects the dose;
- l) the means of ceasing conveyor movement or identifying affected product if any fault in the beam occurs.

7 Product definition

7.1 Product to be sterilized, including the packaging materials, shall be specified.

7.2 Changes to product, product package, or configuration of product within the package shall be specified (see 12.5.2).

7.3 A system shall be specified and implemented to ensure that the condition of product presented for sterilization, including its bioburden, is controlled so that the effectiveness of the sterilization process is not compromised. The effectiveness of the system shall be demonstrated and shall include determination of bioburden in accordance with ISO 11737-1.

7.4 If a sterilization dose is to be established for a product family, requirements for defining a product family in ISO 11137-2:2006, Clause 4, shall be met.

7.5 If a processing category is to be used for the purpose of routine processing, product shall be assessed against documented criteria as to whether it is to be included in a processing category. Assessment shall include consideration of product-related variables that affect dose to product and processing specification. The outcome of the assessment shall be recorded (see 4.1.2).

7.6 Periodic reviews of the criteria for assessing product for inclusion in a processing category and of the group of product that constitutes a processing category shall be conducted. The outcome of such reviews shall be recorded (see 4.1.2).

8 Process definition

8.1 Establishing the maximum acceptable dose

8.1.1 The maximum acceptable dose for product shall be established. When treated with the maximum acceptable dose, product shall meet its specified functional requirements throughout its defined lifetime.

8.1.2 Basic technical requirements to establish the maximum acceptable dose shall include:

- a) a facility capable of assessing product with regard to its intended function;
- b) product representative of that to be produced routinely;
- c) an appropriate source of radiation capable of precisely and accurately delivering the required doses (see also 8.4.1).

8.2 Establishing the sterilization dose

8.2.1 The sterilization dose shall be established for product.

8.2.2 One of two approaches, as described in a) and b) below, shall be taken in establishing the sterilization dose:

- a) a knowledge of the number and/or resistance to radiation of the bioburden is obtained and used to set the sterilization dose

NOTE Methods of setting the sterilization dose and circumstances under which these methods may be applied are detailed in 6.1 of ISO 11137-2:2006.

or

- b) a sterilization dose of 25 kGy or 15 kGy is selected and substantiated; in substantiating a sterilization dose of 25 kGy or 15 kGy, the primary manufacturer shall have evidence that the selected sterilization dose is capable of achieving the specified requirements for sterility (see 1.2.2).

NOTE Methods VD_{max}^{25} and VD_{max}^{15} for substantiation of the sterilization dose and circumstances under which these methods may be applied are detailed in 6.2 of ISO 11137-2:2006. Methods VD_{max}^{25} and VD_{max}^{15} are linked to achievement of a sterility assurance level of 10^{-6} .

8.2.3 Basic technical requirements to establish the sterilization dose shall include:

- a) a competent microbiological laboratory to perform determinations of bioburden in accordance with ISO 11737-1 and tests of sterility in accordance with ISO 11737-2;
- b) product representative of that to be produced routinely;
- c) an appropriate source of radiation capable of precisely and accurately delivering the required doses (see also 8.4.2).

NOTE Guidance on dosimetric aspects of radiation sterilization can be found in ISO 11137-3.

8.3 Specifying the maximum acceptable dose and the sterilization dose

The sterilization dose and the maximum acceptable dose shall be specified for product.

8.4 Transference of maximum acceptable, verification, or sterilization dose between radiation sources

8.4.1 Transference of maximum acceptable dose

In transferring a maximum acceptable dose to a radiation source different from that on which the dose was originally established, an assessment shall be made demonstrating that differences in irradiation conditions of the two radiation sources do not affect the validity of the dose. The assessment shall be documented and the outcome shall be recorded (see 4.1.2).

8.4.2 Transference of verification dose or sterilization dose

8.4.2.1 Transference of a verification dose or a sterilization dose to a radiation source different from that on which the dose was originally established shall not be permitted unless:

- a) data are available to demonstrate that differences in operating conditions of the two radiation sources have no effect on microbicidal effectiveness

or

- b) 8.4.2.2 or 8.4.2.3 applies.

8.4.2.2 For product that does not contain water in the liquid state, transference of the verification dose or sterilization dose is permitted between:

- a) one gamma irradiator and another gamma irradiator,
- b) one electron beam generator and another electron beam generator

or

- c) one X-ray generator and another X-ray generator.

8.4.2.3 For product that contains water in the liquid state, transference of the verification dose or sterilization dose is permitted between:

- a) one gamma irradiator and another gamma irradiator,
- b) two electron radiation sources operating under identical operating conditions

or

- c) two X-ray radiation sources operating under identical operating conditions.

9 Validation

9.1 Installation qualification

9.1.1 Operating procedures for the irradiator and associated conveyor system shall be specified.

9.1.2 Process and ancillary equipment, including associated software, shall be tested to verify operation to design specifications. The test method(s) shall be documented and the results shall be recorded (see 4.1.2).

9.1.3 Any modifications made to the irradiator during installation shall be documented (see 6.2.1).

9.1.4 For gamma irradiators, the activity of the source and a description of the location of individual components of the source shall be recorded (see 4.1.2).

9.1.5 For electron beam irradiators, the characteristics of the beam (electron energy, average beam current and, if applicable, scan width and scan uniformity) shall be determined and recorded (see 4.1.2).

9.1.6 For X-ray irradiators, the characteristics of the beam (electron or X-ray energy, average beam current and, if applicable, scan width and scan uniformity) shall be determined and recorded (see 4.1.2).

9.2 Operational qualification

9.2.1 Prior to operational qualification (OQ), the calibration of all instrumentation, including test instrumentation used for monitoring, controlling, indicating, or recording, shall be confirmed (see 4.3.3).

9.2.2 OQ shall be carried out by irradiating homogeneous material representative of product to be processed to demonstrate the capability of the equipment to deliver the range of doses required for the sterilization process that has been specified (see Clause 8). OQ shall demonstrate that the irradiator, as installed, is capable of operating and delivering appropriate doses within defined acceptance criteria.

9.2.3 Dose mapping shall be carried out to characterize the irradiator with respect to the distribution of dose (see 9.2.4) and variability of dose (see 9.2.5).

NOTE Guidance on dose mapping is given in ISO 11137-3.

9.2.4 Dose mapping shall be carried out using an irradiation container filled to the upper limit of its design specification with material of homogeneous density. Dosimeters shall be used to determine the dose at various known depths in the material. During dose mapping, irradiation containers, filled to the upper limit of their design specifications with the same material as that present in the container being dose mapped, shall be present in the irradiator in sufficient numbers to mimic effectively a fully loaded irradiator.

9.2.5 Dose mapping shall be carried out on a sufficient number of irradiation containers to allow determination of the distribution and variability of dose between irradiation containers.

9.2.6 If there is more than one conveyor path, dose mapping shall be carried out for each path to be used for processing product.

9.2.7 The effect of a process interruption on the dose shall be determined and recorded (see 4.1.2).

9.2.8 Records of dose mapping shall include a description of irradiation containers, irradiator operating conditions, materials used, measurements of dose and conclusions drawn (see 4.1.2).

9.2.9 For gamma irradiators, the relationship between the timer setting, conveyor speed and dose shall be established.

9.2.10 For electron beam and X-ray irradiators, variations in the characteristics of the beam (see 9.1.5 or 9.1.6) during dose mapping shall be within the limits of the irradiator specification (see 6.2.4 or 6.2.5).

9.2.11 For electron beam and X-ray irradiators, the relationship between the characteristics of the beam (see 9.1.5 and 9.1.6), the conveyor speed and dose shall be established.

9.3 Performance qualification

9.3.1 Dose mapping shall be carried out using product loaded in irradiation containers in accordance with a specified loading pattern in order to

- a) identify the location and magnitude of the minimum and maximum dose and
- b) determine the relationships between the minimum and maximum dose and the dose(s) at the routine monitoring position(s).

9.3.2 The manner of presenting product for sterilization shall be specified. This shall include:

- a) the dimensions and density of packaged product;
- b) the orientation of product within the package;
- c) a description of the irradiation container (if multiple types of irradiation containers are used within the irradiator);
- d) a description of the conveyor path (if multiple conveyor paths are used within the irradiator).

9.3.3 Dose mapping shall be carried out for each processing category (see 7.5).

9.3.4 If partially filled irradiation containers are to be used during routine processing, the effect of partial filling on

- a) dose distribution within irradiation containers and
- b) dose and dose distribution in other irradiation containers present in the irradiator,

shall be determined and recorded (see 4.1.2).

9.3.5 Dose mapping shall be carried out on representative irradiation containers sufficient in number to determine the variability of dose between containers.

9.3.6 Dose mapping shall be carried out for each conveyor path to be used for processing the defined product.

9.3.7 For gamma and X-ray irradiators, dose mapping shall be carried out to identify product, or processing categories if used, that can be processed with the product being mapped. The effect on dose to product of different densities present in the irradiator shall be determined to define product that can be processed together.

9.3.8 Records of dose mapping shall include a description of the irradiation container, loading pattern, conveyor path, irradiator operating conditions, measurements of dose and conclusions drawn (see 4.1.2).

9.4 Review and approval of validation

9.4.1 Information generated during installation qualification (IQ), OQ and performance qualification (PQ) shall be reviewed. The outcome of the review shall be recorded (see 4.1.2).

9.4.2 From a consideration of the information and its review, a process specification shall be prepared (see 4.1.2).

9.4.3 For gamma irradiation, the process specification shall include:

- a) the description of packaged product, including dimensions, density and orientation of product within the package (see Clause 7 and 9.3.2,) and acceptable variations;
- b) the loading pattern of product within the irradiation container (see 9.3.1);
- c) the conveyor path(s) to be used (see 9.3.6);
- d) the maximum acceptable dose (see 8.1);
- e) the sterilization dose (see 8.2);
- f) for product that support microbial growth, the maximal interval of time between manufacture and completion of irradiation;
- g) the routine dosimeter monitoring position(s);
- h) the relationships between the dose at the monitoring position(s) and the minimum and maximum doses (see 9.3.1);
- i) for product that is to be given multiple exposures to the radiation field, any required re-orientation between exposures.

9.4.4 For electron beam and X-ray irradiation, the process specification shall include:

- a) the description of packaged product, including dimensions, density and orientation of product within the package (see Clause 7 and 9.3.2) and acceptable variations;
- b) the loading pattern of product within the irradiation container (see 9.3.1);
- c) the conveyor path(s) to be used (see 9.3.6);
- d) the maximum acceptable dose (see 8.1);
- e) the sterilization dose (see 8.2);
- f) for product that support microbial growth, the maximal interval of time between manufacture and completion of irradiation;
- g) the routine dosimeter monitoring position(s);
- h) the relationships between the dose at the monitoring position(s) and the minimum and maximum doses (see 9.3.1);
- i) the irradiator operating conditions and limits (i.e. beam characteristics and conveyor speed);
- j) for product that is to be given multiple exposures to the radiation field, any required re-orientation between exposures.

10 Routine monitoring and control

10.1 Procedures for handling of product and maintaining product integrity before, during and after irradiation shall be specified.

10.2 Systems for counting product and checking product count shall be implemented throughout product receipt, loading, unloading, handling and release. Any discrepancies in the count shall be resolved before processing and/or release.

10.3 Non-irradiated and irradiated product shall be segregated.

10.4 Radiation sensitive visual indicators shall not be used as proof of adequate radiation processing or as the sole means of differentiating irradiated products from non-irradiated products.

10.5 Product shall be loaded into the irradiation container in accordance with the process specification (see 9.4.3 or 9.4.4).

10.6 A dosimeter or dosimeters shall be placed at the predetermined routine monitoring position(s). Following irradiation, the dosimeters shall be measured and the results recorded (see 4.1.2) and analyzed.

10.7 The frequency of dosimeter placement shall be sufficient to verify that the process is in control. The frequency and its rationale shall be specified.

10.8 For gamma irradiators:

- a) the timer setting and/or conveyor speed shall be adjusted in accordance with a documented procedure to take account of radionuclide decay and
- b) the source position, timer setting and/or conveyor speed and the movement of irradiation containers shall be monitored and recorded (see 4.1.2).

10.9 For electron beam and X-ray irradiators, the electron beam characteristics (see 9.1.5 and 9.1.6) and conveyor speed shall be monitored and recorded (see 4.1.2).

10.10 If process interruption(s) and/or process non-conformance(s) occur, they shall be recorded, together with any actions taken (see 4.1.2).

10.11 Records of radiation processing shall state the date of irradiation and be traceable to batch records (see 4.3.2).

11 Product release from sterilization

11.1 Prior to product release from sterilization, any specific periodic tests, calibrations, maintenance tasks and necessary requalification shall have been performed and outcomes recorded (see 4.1.2).

11.2 Procedures for review of records and product release from sterilization shall be specified (see 4.1.2). The procedure(s) shall define the requirements (see 9.4.3 or 9.4.4 as appropriate) for designating a sterilization process as conforming, taking into account the uncertainty of the measurement system(s). If these requirements are not met, product shall be considered as nonconforming and handled in accordance with 4.4.

Additional records of manufacture and inspection of product will be required as specified in a quality management system (see ISO 13485) in order for product to be released as sterile and distributed.

12 Maintaining process effectiveness

12.1 Demonstration of continued effectiveness

12.1.1 General

The continued effectiveness of the established sterilization dose shall be demonstrated through the conduct of

- a) determinations of bioburden to monitor the number of microorganisms present on product in relation to a defined bioburden specification, and
- b) sterilization dose audits to monitor the radiation resistance of the bioburden on product.

NOTE The method for the performance of a sterilization dose audit, described in ISO 11137-2, includes the conduct of a bioburden determination.

12.1.2 Frequency of determinations of bioburden

12.1.2.1 For product of average bioburden greater than or equal to 1,5, the maximum interval of time between determinations of bioburden shall be three months.

12.1.2.2 For product of average bioburden less than 1.5 and for which a) the sterilization dose has been set using Method 2 (see ISO 11137-2), or b) a sterilization dose of 25 kGy has been selected (see 8.2.2), the maximum interval of time between determinations of bioburden shall be three months.

12.1.2.3 For product of average bioburden less than 1.5 and for which a) the sterilization dose has been set using Method 1 (see ISO 11137-2), or b) a sterilization dose of 15 kGy has been selected (see 8.2.2), the maximum interval of time between determinations of bioburden shall be one month.

12.1.2.4 If the interval of time between the manufacture of batches of product is more than either one month or three months, as applicable (see 12.1.2.1, 12.1.2.2, and 12.1.2.3), determinations of bioburden shall be performed on each production batch.

12.1.2.5 If the outcome of determinations of bioburden exceeds the specified limit, an investigation in accordance with ISO 11737-1 shall be performed. If the outcome of the investigation indicates that the bioburden determination is a true result, action shall be taken in accordance with 4.4 and a sterilization dose audit shall be performed immediately. Depending on the outcome of the sterilization dose audit, a) or b) below shall be followed.

- a) If the sterilization dose audit is unsuccessful, action shall be taken in accordance with 12.1.3.5.
- b) If the outcome of the sterilization dose audit is successful and the bioburden continues to exceed the specified limit, sterilization shall continue using the dose used prior to the sterilization dose audit. Also
 - 1) if the sterilization dose has been established using Method 1 (see ISO 11137-2), a three-month interval for the sterilization dose audit shall be used until either the bioburden is returned to the specified limit or the sterilization dose is re-established;
 - 2) if the sterilization dose has been established using Method 2 (see ISO 11137-2), a three-month interval for the sterilization dose audit shall be used until compliance with 12.1.3.2 is achieved;

- 3) if a sterilization dose of 25 kGy has been selected and substantiated using Method VD_{max}^{25} and the average bioburden is less than 1,000, the sterilization dose audit frequency currently used shall be continued;
- 4) if a sterilization dose of 25 kGy has been selected and substantiated using Method VD_{max}^{25} and the average bioburden is greater than 1,000, the sterilization dose shall be established using another method;
- 5) if a sterilization dose of 15 kGy has been selected and substantiated using Method VD_{max}^{15} and the average bioburden is less than 1.5, the sterilization dose audit frequency currently used shall be continued;
- 6) if a sterilization dose of 15 kGy has been selected and substantiated using Method VD_{max}^{15} and the average bioburden is greater than 1.5, the sterilization dose shall be established using another method.

12.1.3 Frequency of sterilization dose audits

12.1.3.1 One of two possible approaches, described in a) and b) below, shall be made in initially determining the interval of time between the performance of sterilization dose audits:

- a) an interval of time of three months between sterilization dose audits is selected

or

- b) a rationale is prepared and documented for the selection of the initial interval of time between the performance of sterilization dose audits; in preparing the rationale, account shall be taken, and records made, of a review and conclusions reached with respect to, at least:

- 1) the specified limit for bioburden;
- 2) available data from determinations of bioburden, the period of time over which these data were obtained and the characterization of the microorganisms that comprise the bioburden;

NOTE Characterization may be based, for example, on colony or cellular morphology, staining properties, or selective culturing.

- 3) available data on the resistance of microorganisms that comprise the bioburden;
- 4) the method used to establish the sterilization dose and the conservativeness associated with the method;
- 5) the difference between the dose to be used in routine processing and the sterilization dose, together with any conservativeness associated with this difference;
- 6) the materials comprising the product, particularly the use of materials of natural origin, and the control of the microbiological quality of materials;
- 7) the manufacturing process, particularly manufacturing steps that affect bioburden or its resistance;
- 8) the control and monitoring procedures for the manufacturing process;
- 9) the interval of time between manufacture of batches of product;

- 10) the manufacturing environment, particularly the extent of microbiological control and monitoring and available data on the stability of the manufacturing environment over time;
- 11) the controls on the health, cleanliness and clothing of personnel in the manufacturing area; and
- 12) available data on the microbiological quality of other products in the same product family.

12.1.3.2 An increase in the interval of time between the performance of sterilization dose audits shall only be permitted if:

- a) at least four consecutive sterilization dose audits, whose outcomes have required neither dose augmentation nor sterilization dose re-establishment, have been performed at the previously selected interval of time;
- b) data are available that demonstrate the stability of bioburden within the bioburden specification over the same period of time as item a) above; these include
 - 1) bioburden determinations performed at least every three months and
 - 2) characterization of bioburden (e.g. use of colony or cellular morphology, staining properties or selective culturing);
- c) the manufacture of the product in relation to bioburden is controlled and the effectiveness of this control is demonstrated through the implementation of the elements of a quality management system identified for sterile medical devices in ISO 13485.

12.1.3.3 Unless 12.1.3.4 applies, the maximum interval of time between performance of sterilization dose audits shall be twelve months.

12.1.3.4 If the interval of time between manufacture of batches of product is more than that determined in accordance with 12.1.3.1 and/or 12.1.3.2, a sterilization dose audit shall be performed on each production batch.

12.1.3.5 If a sterilization dose audit is unsuccessful, action shall be taken in accordance with ISO 11137-2:2006, Clause 10. The frequency of performance of sterilization dose audits shall be an interval of time of not greater than three months until:

- a) the cause of the sterilization dose audit failure or the increase in bioburden has been investigated and correction and/or corrective action implemented;
- b) the rationale (see 12.1.3.1) for the interval of time between the performance of sterilization dose audits has been reviewed and, if necessary, a new interval of time specified;
- c) the criteria for increasing the interval of time between the performance of sterilization dose audits in 12.1.3.2 have been met.

12.2 Recalibration

The accuracy and reliability of instrumentation used to control, indicate or record the sterilization process shall be verified periodically in accordance with 4.3.3.

12.3 Maintenance of equipment

12.3.1 Preventative maintenance shall be planned and performed in accordance with documented procedures. Records of maintenance shall be retained (see 4.1.2).

12.3.2 The maintenance scheme, maintenance procedures and maintenance records shall be reviewed at specified intervals by a designated person and the results of the review shall be documented.

12.4 Requalification of equipment

12.4.1 Requalification of a sterilization process shall be carried out for defined product and specified equipment; it shall be performed at defined intervals and after the assessment of any change (see 12.5). The extent to which requalification is carried out shall be justified.

12.4.2 Requalification procedures shall be specified and records of requalification retained (see 4.1.2).

12.4.3 Requalification data shall be reviewed against specified acceptance criteria in accordance with documented procedures. Records shall be retained (see 4.1.2) of reviews of requalification data, together with corrections made and corrective actions taken when the specified acceptance criteria are not met.

12.5 Assessment of change

12.5.1 Any change in the irradiator which could affect dose or dose distribution shall be assessed. If one or both of these is judged to be affected, then a repeat of part or all of IQ, OQ, and/or PQ shall be carried out (see 9.1, 9.2 or 9.3). The outcome of the assessment, including the rationale for decisions reached, shall be recorded (see 4.1.2).

12.5.2 A change in product, its package or the presentation of product for sterilization shall be assessed for its effect on the appropriateness of the sterilization process. Those parts of process definition or PQ that have to be undertaken shall be determined based on the nature of the change. The outcome of the assessment, including the rationale for decisions reached, shall be recorded (see 4.1.2).

Annex A **(informative)**

Guidance

NOTE 1 The guidance given in this annex is not intended as a checklist for assessing compliance with this part of ISO 11137. This guidance is intended to assist in obtaining a uniform understanding and implementation of this part of ISO 11137 by providing explanations and acceptable methods for achieving compliance with specified requirements. Methods other than those given in the guidance may be used. However, the use of alternative methods has to be demonstrated to be effective in achieving compliance with this part of ISO 11137.

NOTE 2 For ease of reference, the numbering in this annex corresponds to that in the normative part of this part of ISO 11137.

A.1 Scope

A.1.1 No guidance offered.

A.1.2 No guidance offered.

A.1.2.1 No guidance offered.

A.1.2.2 The effective implementation of defined and documented procedures is necessary for the development, validation and routine control of a sterilization process for medical devices. Such procedures are commonly considered to be elements of a quality management system. This part of ISO 11137 identifies and specifies those elements of a quality management system that are essential for the effective control of sterilization by normative reference to the quality management system standard for medical devices, ISO 13485. This part of ISO 11137 does not require that a complete quality management system complying with ISO 13485 be implemented, nor does it require that those quality management system elements that are specified be subject to third party assessment. Attention is drawn to the existence of national and regional regulatory requirements for quality management systems in the manufacture of medical devices and for third party assessment of such systems.

A.1.2.3 The use of biological indicators for validation and process monitoring is not recommended for radiation sterilization because the relationship between the microbicidal action and radiation dose is well established.

A.1.2.4 No guidance offered.

A.1.2.5 No guidance offered.

A.2 Normative references

The requirements given in documents included as normative references are requirements of this part of ISO 11137 only to the extent that they are cited in a normative part of this document; the citation may be to an entire standard or limited to specific clauses.

A.3 Terms and definitions

No guidance offered.

A.4 Quality management system elements

NOTE See also A.1.2.2.

A.4.1 Documentation

Requirements for control of documents and records are specified in 4.2.3 and 4.2.4 respectively, of ISO 13485:2003.

In ISO 13485:2003, the requirements for documentation relate to the generation and control of documentation (including specifications and procedures) and records.

A.4.2 Management responsibility

Requirements for responsibility and authority are specified in 5.5 of ISO 13485:2003 and requirements for human resources are specified in 6.2 of ISO 13485:2003.

In ISO 13485:2003, the requirements for management responsibility relate to management commitment, customer focus, quality policy, planning, responsibility, authority and communication, and management review.

The development, validation and routine control of a sterilization process can involve a number of separate parties, each of whom is responsible for certain elements. This part of ISO 11137 requires that the party accepting particular responsibilities be defined and that this definition of responsibilities be documented. This definition of authority and responsibility is documented within the quality management system(s) of the identified parties. The party accepting responsibilities for defined elements is required to assign these elements to competent personnel, with competence demonstrated through appropriate training and qualification.

In radiation sterilization, there can be two principal parties involved; the primary manufacturer and the irradiator operator. The irradiator operator might be a specialist contractor offering a sterilization service or it might be part of the same firm as the primary manufacturer. In these instances, the primary manufacturer and the irradiator operator have separate quality management systems and the definition of authority and responsibility is within a contract or technical agreement. Some of the principal responsibilities that can be allocated to the primary manufacturer and irradiator operator are:

a) Primary manufacturer

- establishing the sterilization dose;
- developing product families;
- establishing the maximum acceptable dose;
- PQ;
- controlling the manufacturing process(es), including meeting the specifications for products submitted to the irradiator's operator, i.e. product density, orientation, dimensions;

- revision of specifications submitted to the irradiator's operator;
- change control of the product to include a review of product-related variables that affect processing categories;
- control of product labeled “sterile” prior to sterilization;
- product release.

b) Irradiator operator

- IQ;
- OQ;
- controlling the irradiation process;
- change control of the irradiator;
- certification of the radiation dose;
- developing processing categories.

A.4.3 Product realization

NOTE In ISO 13485:2003, the requirements for product realization relate to the product lifecycle from the determination of customer requirements, design and development, purchasing, control of production and calibration of monitoring and measuring devices.

A.4.3.1 Requirements for purchasing are specified in 7.4 of ISO 13485:2003. In particular, it should be noted that the requirements in 7.4.3 of ISO 13485:2003 for verification of purchased product apply to all product and services received from outside the organization.

A.4.3.2 Requirements for identification and traceability are specified in 7.5.3 of ISO 13485:2003.

A.4.3.3 Requirements for calibration of monitoring and measuring devices are specified in 7.6 of ISO 13485:2003.

A.4.3.4 Guidance on dosimetric aspects of radiation sterilization is given in ISO 11137-3.

A.4.4 Measurement, analysis and improvement — Control of nonconforming product

Procedures for control of nonconforming product and corrective action are specified in 8.3 and 8.5.2 respectively, of ISO 13485:2003.

In ISO 13485:2003, the requirements for measurement, analysis and improvement relate to process monitoring, control of nonconforming product, analysis of data, and improvement (including corrective and preventive actions).

A.5 Sterilizing agent characterization

A.5.1 Sterilizing agent

The assessment of the potential of electrons or X-rays above the specified energy level for inducing radioactive radionuclides in irradiated product should be based on available literature, measurement of induced radioactivity and/or modeling of induced radioactivity.

An example of an assessment using both experimental and theoretical treatments is that of Grégoire *et al.* [21]. Measured and calculated values of the induced radioactivity in many materials used in medical devices and irradiated with X-rays generated with a 7.5 MeV electron beam at doses up to 50 kGy are reported. Such materials are:

- a) materials that have very small potential for becoming radioactive (non-metallic hydrocarbon-based materials, e.g. polyethylene and polystyrene);
- b) materials that have a potential to be activated at a measurable but low level (e.g. stainless steel and brass);
- c) materials that have a potential to be activated to comparatively higher levels (e.g. tantalum) requiring detailed evaluation.

Materials not covered in the publication of Grégoire *et al.* [21] could require detailed evaluation due to their potential for activity (e.g. silver and gold).

A.5.2 Microbicidal effectiveness

No guidance offered.

A.5.3 Material effects

No guidance offered.

A.5.4 Environmental considerations

Principles of an environmental management system can be applied to the radiation sterilization process. ISO 14001 provides a specification for an environmental management system. ISO 14040 provides guidance on designing a life cycle assessment study. An assessment should be made regarding any explosive or inflammable properties of materials to be irradiated.

A.6 Process and equipment characterization

NOTE The purpose of this activity is to define the equipment used in the sterilization process and its operation.

A.6.1 No guidance offered.

A.6.2 No guidance offered.

A.7 Product definition

NOTE The purpose of product definition is to define the product to be sterilized and to determine its microbiological quality prior to sterilization.

A.7.1 No guidance offered.

A.7.2 No guidance offered.

A.7.3 The intention is that the bioburden is stable and low, taking into account the nature of the raw materials, product packaging and procedures prior to sterilization. This is typically achieved by using a quality management system complying with ISO 13485 throughout the manufacture of the medical device.

A.7.4 See ISO 11137-2:2006, Clause 4.

A.7.5 The criteria for assessing product for inclusion in processing categories are unique to radiation sterilization and would not necessarily be appropriate for use with other sterilization methods (e.g. ethylene oxide or moist heat).

For gamma or an X-ray irradiator, routine processing of product is performed in an irradiation facility that typically contains a large number of irradiation containers. The effect of product in adjacent irradiation containers on the dose is determined during OQ dose mapping and can provide information regarding products that can be processed together. Typically, this dose mapping information is also used to assess product for inclusion in a processing category that can be used by the irradiator operator to schedule the product being processed.

The two main criteria for assessing product for inclusion in a processing category for gamma and X-ray irradiators are possession of similar dose requirements (sterilization dose and maximum acceptable dose) and dose absorption characteristics (e.g. density and loading pattern). In general, product is included in a processing category based on the ability to process product at the same timer setting without violating the specified dose limits for product within the processing category. If OQ dose mapping has not been performed to determine the ranges of products that may be included in a processing category, each product to be included in the processing category should be dose mapped.

For electron beam irradiators, more individual product dose mapping during PQ is performed than for X-ray or gamma irradiators. However, to reduce the amount of dose mapping required, product may be grouped into processing categories. Grouping of product into processing categories is only appropriate if the product, packaging and the loading pattern of product in irradiation containers result in an ability to process product at the same process parameters without exceeding the specified dose limits for product within the processing category. The number, distribution and orientation of product within the irradiation container and density and distribution of mass should be considered.

Modifications of the product-related variables that affect dose to product and processing specifications can alter the basis on which product was included in the processing category; when this occurs, a new processing category should be defined. Examples of these product-related variables include:

- a) the dimensions of the carton;
- b) the weight of the carton including product;
- c) the orientation of product within the carton;
- d) the number of product items per carton;
- e) the sterilization dose;

f) the maximum acceptable dose.

A.7.6 Periodic reviews of processing categories are typically carried out annually.

A.8 Process definition

NOTE The purpose of process definition is to establish the maximum acceptable dose and the sterilization dose for the sterilization process to be applied to defined product (see Clause 7).

A.8.1 Establishing the maximum acceptable dose

A.8.1.1 Assurance of the quality, safety and performance of product throughout defined lifetime should begin with the selection of appropriate materials (see AAMI TIR17 ^[16]). Typically, in designing a test program, variations in the following should be assessed:

- raw materials;
- manufacturing processes;
- radiation dose;
- type of radiation;
- storage conditions after irradiation.

The program should include assessment of functionality and safety, including biological safety (see ISO 10993-1), using appropriate tests with specific acceptance criteria.

The dose derived from the test program is used to determine the maximum acceptable dose for product.

A further necessary step in the test program is to obtain supporting evidence that the product will meet its acceptance criteria throughout its defined lifetime. One method designed to obtain this information more rapidly than by real time experience is through the institution of an accelerated aging program. The adverse effects of radiation on product develop more rapidly at higher temperatures and proposals have been made for relating the heat induced changes to those occurring in real time (see AAMI TIR17 ^[16]). Accelerated ageing, however, is not a substitute for real time ageing.

See ISO 11137-3:2006, Clause 6, for further guidance on dosimetry aspects.

A.8.1.2 Guidance on dosimetric aspects of radiation sterilization is given in ISO 11137-3.

A.8.2 Establishing the sterilization dose

A.8.2.1 See ISO 11137-2.

A.8.2.2 With regard to 8.2.2 a), in order to establish the sterilization dose with this approach, the following can apply:

- 1) a knowledge of the number and resistance of microorganisms comprising the bioburden may be used in establishing the sterilization dose for product having an average bioburden greater than or equal to 0,1 (see ISO 11137-2:2006, Clause 7);

- 2) a knowledge of the resistance of microorganisms comprising the bioburden may be used in establishing the sterilization dose for product having any level of average bioburden, (see ISO 11137-2:2006, Clause 8.)

With regard to 8.2.2 b), an appropriate method for substantiation of 25 kGy for product having an average bioburden less than or equal to 1 000 or for substantiation of 15 kGy for product having an average bioburden ≤ 1.5 is given in ISO 11137-2:2006, Clause 9.

A.8.2.3 No guidance offered.

A.8.3 Specifying the maximum acceptable dose and the sterilization dose

No guidance offered.

A.8.4 Transference of maximum acceptable, verification, or sterilization dose between radiation sources

A.8.4.1 Transference of maximum acceptable dose

The assessment of the validity of the maximum acceptable dose for a radiation source other than that on which the dose was originally established should take into consideration dose rate and product temperature during irradiation. For example, the higher the dose rate, the lower the unwanted effects upon product.

A product qualified at a low dose rate (gamma or X-rays) will typically require minimal qualification to demonstrate material compatibility at a higher dose rate (electron-beam). Conversely, a material qualified at a high dose rate may require more substantial qualification in the low dose rate application.

If dose rate and product temperature are equivalent, transfer between the same type of radiation sources is appropriate.

A.8.4.2 Transference of verification or sterilization dose

A.8.4.2.1 There is a concern in transferring between types of radiation source with widely differing dose rates that can provide different microbicidal effects. Demonstrating that the microbicidal effectiveness is not affected by the change in dose rate provides the necessary data for the transference to be permitted.

A.8.4.2.2 Experimental evidence indicates that when irradiation occurs under “dry” conditions, microbicidal effectiveness is independent of the operating conditions of the sources; hence the granting of this permission.

With regard to item 8.4.2.2 b), a difference in dose rate is of concern when transferring between types of radiation sources; dose rate can alter the microbicidal effectiveness. This comparison to demonstrate that transference does not alter microbial effectiveness can be accomplished by the performance of a successful verification dose experiment (see ISO 11137-2) using the radiation source to which transfer is being considered.

A.8.4.2.3 Demonstration that the microbicidal effectiveness is not affected by the change in dose rate provides the necessary data for the transference to be permitted. Available experimental evidence indicates that when irradiation occurs in the presence of liquid water, microbicidal effectiveness can be affected by the operating characteristics of the radiation sources; hence the restrictions on permission being granted. Such a demonstration can be accomplished by the performance of a successful verification dose experiment using the radiation source to which transfer is being considered (see ISO 11137-2).

A.9 Validation

NOTE 1 For the purpose of this part of ISO 11137, validation has at least the three main elements, IQ, OQ, and PQ.

NOTE 2 For major installations or new items of equipment, it is common practice to begin by defining and documenting the user requirements. When potential suppliers of equipment have been identified, the equipment specifications and facility layout are formally reviewed against the user requirements and any discrepancies resolved. This process is generally designated Design Qualification (DQ). This part of ISO 11137 does not specify requirements for DQ.

A.9.1 Installation qualification

IQ is carried out to demonstrate that the sterilization equipment and any ancillary items have been supplied and installed in accordance with their specification.

IQ begins with production of documentation describing the design and installation requirements (see also A.9, NOTE 2). IQ should be based on written requirements. Construction and installation should be assessed against these requirements. IQ documentation should include drawings and details of all the construction materials, the dimensions and tolerances of the equipment, support services and power supplies.

IQ should be completed prior to performance of OQ.

Radiation plants that operated prior to the publication of ISO 11137:1995 might not have records of modifications made to the irradiator during installation. Retrospective generation of such records is not required.

A.9.2 Operational qualification

See ISO 11137-3 for dosimetric aspects for radiation sterilization.

A.9.3 Performance qualification

PQ is the stage of validation which uses defined product to demonstrate that equipment consistently operates in accordance with predetermined criteria to deliver doses within the range of the specified doses, thereby giving product that meets the specified requirement for sterility.

See ISO 11137-3 for dosimetric aspects for radiation sterilization.

With regard to 9.3.2 b), orientation of the product within the package is critical in electron-beam processing. Furthermore, orientation can be critical in gamma and X-ray processing where density could affect dose distribution (e.g. containers of liquids or metal hip implants).

With regard to 9.3.2 c), if a system is used to secure the product in the irradiation container, a description of the materials used and the method of securing should be included in the specification.

A.9.4 Review and approval of validation

This activity involves undertaking and documenting a review of the validation data to confirm the acceptability of the sterilization process and to develop and approve a process specification.

A.10 Routine monitoring and control

NOTE The purpose of routine monitoring and control is to demonstrate that the validated and specified sterilization process has been delivered to product.

A.10.1 No guidance offered.

A.10.2 ISO 13485 specifies requirements for handling and preservation of product.

A.10.3 When segregating product, consideration can be given to:

a) the physical separation of product

and/or

b) the use of a reliable inventory control system.

The use of labels and/or stamps could be part of the procedure.

A.10.4 No guidance offered.

A.10.5 If product could move within the irradiation container and, in so doing, affect dose distribution, then product should be secured and packing material should be utilized to prevent undue movement during processing.

A.10.6 A review of the results from the monitoring of the process parameters and from routine dosimetry is used to ascertain that product has been processed according to specification. The review should include, if appropriate, actions to be taken when measurements fall outside specified limits.

For measurements outside of specified limits, a procedure describing the actions to be taken in such cases (e.g. reprocessing, checking of the reliability of the transgressing reading, product discard, further processing needs) should be documented and implemented.

Electron beam irradiators vary in their characteristics and in the way they are monitored. The relative contribution of the monitoring of operating parameters and of the performance of routine dosimetry to assure that the sterilization dose is delivered to product inevitably varies from irradiator to irradiator. The irradiator operator should design a monitoring procedure, including the monitoring of operating parameters and the performance of routine dosimetry, which will provide the necessary confidence that sterilization processing is properly carried out.

A.10.7 See ISO 11137-3 for guidance on dosimetric aspects.

A.10.8 No guidance offered.

A.10.9 No guidance offered.

A.10.10 A review of the results from the monitoring of the process parameters and from routine dosimetry is used to ascertain that product has been processed according to specification. The review should also include, if appropriate, actions to be taken in case of process interruption.

Deviations from normal operating conditions (such as power loss or incorrect conveyor movements) should result in immediate interruption of the process and automatic safe storage of the source. The reason for and the duration of process interruption should be recorded, and procedures regarding restart should be documented and implemented.

In case of failure of the irradiator or conveyor system, a documented procedure should be followed to ensure that subsequent actions provide product that has received the sterilization dose and that the maximum acceptable dose has not been exceeded.

For process interruption occurring with product incapable of supporting microbial growth, interruption without moving product in the irradiator does not generally necessitate action. Nevertheless, such process interruptions should be documented and reviewed to ensure that dosimetry measurements are valid.

For process interruption occurring with product capable of supporting microbial growth:

- the maximal interval of time that can elapse between completion of manufacture and completion of sterilization processing and
- the conditions of storage and transportation to be applied during this interval of time

are stated in the process specification.

The maximal interval of time and conditions are chosen to ensure that the microbiological quality of the product is at a level that would not compromise product sterility. If process interruption occurs during sterilization and this delays the completion of sterilization beyond the specified time, its effect on the microbiological quality of the product should be ascertained and appropriate action taken. This can include product discard.

If a process deviation occurs resulting in a dose less than the desired dose, additional dose may be given to the product if a) the ability of the product to support microbial growth has been taken into consideration and b) the dose can be delivered in such a way to assure that the minimum dose is achieved and the maximum acceptable dose is not exceeded. See ISO 11137-3 for further guidance.

See ISO 11137-3 for guidance on dosimetric aspects.

A.10.11 No guidance offered.

A.11 Product release from sterilization

No guidance offered.

A.12 Maintaining process effectiveness

A.12.1 Demonstration of continued effectiveness

A.12.1.1 General

For the sterilization dose to remain valid, product has to be manufactured under controlled conditions that yield stable bioburden in terms of numbers and types of microorganisms. To demonstrate continued validity of the sterilization dose, sterilization dose audits are carried out at a pre-defined interval of time.

These specified maximal intervals of time have been based on:

- a) experience gained in applying dose setting methods;
- b) the need to detect changes in manufacturing processes and materials and a consensus on an accepted degree of risk associated with the frequency of seeking such changes;
- c) the potential for seasonal changes or other variations in the microbiological quality of materials or the manufacturing environment;
- d) the generally accepted frequency of revalidation for a sterilization process.

A.12.1.2 Frequency of determinations of bioburden

A.12.1.2.1 No guidance offered.

A.12.1.2.2 No guidance offered.

A.12.1.2.3 No guidance offered.

A.12.1.2.4 No guidance offered.

A.12.1.2.5 In specifying a bioburden limit for the purpose of demonstrating the continued effectiveness of the sterilization dose, the limit should be specified based on the consequences of exceeding the limit on achievement of the specified requirements for sterility. See also ISO 11737-1 for information on setting bioburden limits for other purposes.

A.12.1.3 Frequency of sterilization dose audits

A.12.1.3.1

- a) Historically, a three-month time interval has been used to detect seasonal variations in bioburden. Product manufactured under controlled conditions may not exhibit seasonal variation in bioburden. If control over bioburden in terms of numbers and types of microorganisms can be demonstrated with no seasonal variation, a reduction in the frequency of dose audits may be considered. This consideration has to include those aspects of processing and monitoring specified in 12.1.3. It is noted that all the aspects have to be considered, but not all of them will necessarily provide definitive outcomes or carry equal weight (i.e. be of equal importance).
- b) No guidance offered.

A.12.1.3.2 As experience of product and its manufacture is gained, increases in the interval of time between the performance of sterilization dose audits have occurred as follows – initially an interval of time of three months, then an interval of time of six months and finally an interval of time of twelve months.

It should be recognized that a reduction in the frequency of performance of the sterilization dose audit results in a reduction in the ability to detect a change within the manufacturing process, over time. Consequently, the effect of such a reduction in frequency should be considered before proceeding.

A.12.1.3.3 No guidance offered.

A.12.1.3.4 No guidance offered.

A.12.1.3.5 No guidance offered.

A.12.2 Recalibration

No guidance offered.

A.12.3 Maintenance of equipment

During the review of the maintenance records, the maintenance schedule and procedures should be revised as necessary to address information learned about the equipment.

A.12.4 Requalification of equipment

The intervals for requalification of the irradiator should be chosen to provide assurance that the irradiator is consistently operating within specifications. For gamma irradiators, the requalification is typically carried out in connection with replenishment of sources. For electron beam and X-ray irradiators, requalification is typically carried out on an annual cycle, with specific parts of requalification at shorter time intervals within this cycle. If requalification measurements show that the IQ and/or OQ status of the irradiator has changed, then PQ might have to be repeated.

A.12.5 Assessment of change

A.12.5.1 For gamma irradiators, examples of when OQ should be performed after a change include:

- replenishment of the source;
- changes in source geometry and position;
- changes to the conveyor;
- a change in product path;
- a change in irradiation container.

The extent of the OQ will depend on the type and degree of the change (see Table A.1).

For electron beam irradiators, OQ should be performed when changes are made to the irradiator, which can affect performance. Examples of such changes include:

- changes to the conveyor;
- an increase of maximal designed dimensions of the irradiation container;
- repair or replacement of scanning magnet;
- repair or replacement of bending magnet;
- repair or replacement of parallel beam magnet;
- changes in the elements of the irradiator creating scattering effects.

The extent of the OQ will depend on the type and extent of the change (see Table A.2). For example, an increase of the maximal designed dimensions of the irradiation container will require a complete

requalification, whereas replacement of a conveyor part could only require confirmation of the proper functioning of the conveyor.

For X-ray irradiators, OQ should be performed when changes are made to the irradiator, which can affect performance. Examples of such changes include:

- changes to the conveyor;
- an increase of maximal designed dimensions of the irradiation container;
- repair or replacement of scanning magnet;
- repair or replacement of bending magnet;
- repair or replacement of parallel beam magnet;
- changes in the elements of the irradiator creating scattering effects;
- changes to the X-ray target.

The extent of the OQ will depend on the type and extent of the change (see Table A.3). For example, an increase of the maximal designed dimensions of the irradiation container will require a complete requalification, whereas replacement of a conveyor part could only require confirmation of the proper functioning of the conveyor.

A.12.5.2 No guidance offered.

Table A.1 — Guidance on qualification of changes to a gamma irradiator

Irradiator change	Installation qualification	Operational qualification			
	Installation testing and equipment documentation	Equipment testing	Equipment calibration	Irradiator dose mapping	Type of dose mapping
Addition, removal or reconfiguration of/to radionuclide	✓			✓	Homogeneous material to design limits
Carrier/irradiation container redesign	✓	✓		✓	Homogeneous material to design limits
Removal or relocation of overhead conveyor inside irradiation cell	✓	✓		✓	Homogeneous material to design limits
Removal or relocation of stop units in the critical product path	✓	✓		✓	Homogeneous material to design limits
Removal or relocation of stop units outside of the critical product path	✓	✓			
Replacement of source cables	✓	✓			
Redesign of the source drive system	✓			✓	Transit dose
Redesign that affects the source to product distance	✓	✓		✓	Homogeneous material to design limits Transit dose
Redesign of the source rack system	✓	✓		✓	Homogeneous material to design limits Transit dose
Changes to type of irradiator cycle timer	✓	✓	✓		
Changes to type of irradiator radiation safety monitoring devices	✓	✓	✓		
Changes to type of irradiator pool water monitoring devices	✓	✓	✓ (if applicable)		
NOTE 1 Addition of radionuclide without reconfiguration of the source geometry might only require that part of the homogeneous dose mapping study be performed to confirm the results of mathematical modeling or modification objectives. Whereas addition of radionuclide with change of source geometry might require that all homogeneous dose maps be repeated in addition to some of the ancillary studies such as centre loading or partial load. NOTE 2 Pending results of operational testing (e.g. verification of source position), irradiator dose mapping may be required after source cable replacement. NOTE 3 OQ dose mapping results may lead to a repeat of PQ.					

Table A.2 — Guidance on qualification of changes to an electron beam irradiator

Irradiator change	Installation qualification	Operational qualification			
	Installation testing and equipment documentation	Operational testing	Equipment calibration	Irradiator dose mapping	Type of dose mapping
Accelerator mechanical alignment	✓			✓	Scan uniformity in the direction of beam scan and depth-dose in the direction of beam travel
Steering or focusing magnet systems	✓			✓	Scan uniformity in the direction of beam scan and depth-dose in the direction of beam travel
Bending magnet systems	✓		✓	✓	Scan uniformity in the direction of beam scan and depth-dose in the direction of beam travel
Beam current monitoring system	✓		✓	✓	Scan uniformity in the direction of product travel
Scanning magnet system	✓		✓	✓	Scan uniformity in the direction of beam scan
Conveyor speed monitoring and/or control circuitry	✓		✓	✓	Scan uniformity in the direction of product travel Process interruption testing
Conveyor system motors, belts, and gearing.	✓	✓			
NOTE OQ dose mapping results may lead to a repeat of PQ.					

Table A.3 — Guidance on qualification of changes to an X-ray irradiator

Irradiator change	Installation qualification	Operational qualification			
	Installation testing and equipment documentation	Equipment testing	Equipment calibration	Irradiator dose mapping	Type of dose mapping
Accelerator mechanical alignment	✓			✓	Scan uniformity in the direction of beam scan and depth-dose in the direction of beam travel
Steering or focusing magnet systems	✓			✓	Scan uniformity in the direction of beam scan and depth-dose in the direction of beam travel
Bending magnet systems	✓		✓	✓	Scan uniformity in the direction of beam scan and depth-dose in the direction of beam travel
Beam current monitoring system	✓		✓	✓	Scan uniformity in the direction of product travel
Scanning magnet system	✓		✓	✓	Scan uniformity in the direction of beam scan
Conveyor speed monitoring and/or control circuitry	✓		✓	✓	Scan uniformity in the direction of product travel Process interruption testing
Conveyor system motors, belts and gearing.	✓	✓			
Carrier/irradiation container redesign	✓	✓		✓	Scan uniformity in the direction of product travel Depth-dose in the direction of product travel
Removal or relocation of conveyor inside irradiation cell	✓	✓		✓	Scan uniformity in the direction of product travel Depth-dose in the direction of product travel
Redesign that affects the source-to-product distance	✓	✓		✓	Scan uniformity in the direction of product travel Scan uniformity in the direction of beam scan Depth-dose in the direction of product travel
Changes to type of irradiator radiation safety monitoring devices	✓	✓	✓		
Replacement, redesign, or realignment of the X-ray target	✓	✓		✓	Scan uniformity in the direction of beam scan and beam travel Scan uniformity in the direction of product travel Depth-dose in direction of beam travel
NOTE OQ dose mapping results may lead to a repeat of PQ.					

Bibliography

- [1] ISO 9000:2005, *Quality management systems — Fundamentals and vocabulary*
- [2] ISO 9001:2000, *Quality management systems — Requirements*
- [3] ISO 10993-1:2003, *Biological evaluation of medical devices — Part 1: Evaluation and testing*
- [4] ISO 11137:1995, *Sterilization of health care products — Requirements for validation and routine control — Radiation sterilization*
- [5] ISO 11137-3:2006, *Sterilization of health care products — Radiation — Part 3: Guidance on dosimetric aspects*
- [6] ISO/TS 11139:2006, *Sterilization of health care products — Vocabulary*
- [7] ISO 11607-1, *Packaging for terminally sterilized medical devices — Part 1: Requirements for materials, sterile barrier systems and packaging systems*
- [8] ISO 11607-2, *Packaging for terminally sterilized medical devices — Part 2: Validation requirements for forming, sealing and assembly processes*
- [9] ISO 14001:2004, *Environmental management systems — Requirements with guidance for use*
- [10] ISO 14040:1997, *Environmental management — Life cycle assessment — Principles and framework*
- [11] *International Vocabulary of Basic and General Terms in Metrology (VIM)*, BIPM, IEC, IFCC, ISO, IUPAC, IUPAP, OIML, 2nd ed., 1993 Geneva (1993)
- [12] ISO 22442-1:—¹⁾, *Medical devices utilizing animal tissues and their derivatives — Part 1: Application of risk management*
- [13] ISO 22442-2:—¹⁾, *Medical devices utilizing animal tissues and their derivatives — Part 2: Controls on sourcing, collection and handling*
- [14] ISO 22442-3:—¹⁾, *Medical devices utilizing animal tissues and their derivatives — Part 3: Validation of the elimination and/or inactivation of viruses and transmissible spongiform encephalopathy TSE agents*
- [15] EN 556-1:2001, *Sterilization of Medical Devices — Requirements for medical devices to be designated “STERILE” — Part 1: Requirements for terminally sterilized medical devices*
- [16] AAMI TIR17:1997, *Radiation sterilization — Material qualification*
- [17] ANSI/AAMI ST67:2003, *Sterilization of Medical Devices — Requirements for Products Labeled “Sterile”*

1) To be published.

- [18] ANSI/HGB N43.10-2001, *Safe Design and Use of Panoramic, Wet Source Storage Gamma Irradiators (Category IV) and Dry Source Storage Gamma Irradiators (Category II)*, Health Physics Society, McLean, VA, 2001
- [19] IAEA Safety Series No. 107, *Radiation Safety of Gamma and Electron Irradiation Facilities*, Vienna, 1992
- [20] Global Harmonization Task Force (GHTF) — Study Group 1 (SG1), Document N029R16:2005 — *Information Document concerning the definition of the term "Medical Device"*
- [21] GRÉGOIRE, O., CLELAND, M.R., MITTENDORFER, J., VANDER DONCKT, M. and MEISSNER, J. *Radiological safety of medical devices sterilized with X-rays at 7.5 MeV*, Radiation Physics and Chemistry 67, Issue 2, June 2003, pp. 149-167